Secondary Logo

Journal Logo

Corrigendum

Impact of thymosin α1 as an immunomodulatory therapy on longterm survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis

Author Information
doi: 10.1097/CM9.0000000000001819
  • Open

In the article “Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis” which appeared in vol.134, issue 22, pages 2700–2709 of Chinese Medical Journal,[1] the hazard ratio (HR) values in Figure 3A should be corrected as “HR (12–24 months vs. less than 12 months): 0.463 (95%CI: 0.341–0.683, P = 0.0001); HR (more than 24 months vs. less than 12 months): 0.284 (95%CI: 0.197–0.409, P < 0.0001); HR (12–24 months vs. more than 24 months): 1.632 (95%CI: 1.056–2.522, P = 0.0275).” The HR values in Figure 3B should be corrected as “HR (12–24 months vs. less than 12 months): 0.357 (95%CI: 0.216–0.588, P < 0.0001); HR (more than 24 months vs. less than 12 months): 0.171 (95%CI: 0.107–0.272, P < 0.0001); HR (12–24 months vs. more than 24 months): 2.090 (95%CI: 1.175–3.717, P = 0.0121).” The original results and conclusions are not affected. Figure 3 is corrected as below.

F1
Figure 3:
Kaplan–Meier curves for (A) DFS and (B) OS based on the duration of administration. DFS: Disease-free survival; HR: Hazard ratio; OS: Overall survival.

References

1. Guo CL, Mei JD, Jia YL, Gan FY, Tang YD, Liu CW, et al. Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of nonsmall cell lung cancer patients after R0 resection: a propensity score-matched analysis. Chin Med J 2021; 134:2700–2709. doi: 10.1097/CM9.0000000000001819.
Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.